ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,297.10
-0.21%
US Tech 100
18,079.20
-0.20%
다우존스 지수
39,869.38
-0.10%
Bitcoin
65,539.26
0.46%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Exelixis Inc (EXEL)

  7. Exelixis Inc (EXEL) 뉴스

EXEL

Exelixis (EXEL)

Exelixis Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:EXEL
일자시간출처헤드라인심볼기업
2024/05/1608:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
2024/05/1405:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXELExelixis Inc
2024/05/1105:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EXELExelixis Inc
2024/05/0905:11Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EXELExelixis Inc
2024/05/0905:11Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EXELExelixis Inc
2024/05/0807:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXELExelixis Inc
2024/05/0805:05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in MayNASDAQ:EXELExelixis Inc
2024/05/0105:05Business WireExelixis Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
2024/04/1705:05Business WireExelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024NASDAQ:EXELExelixis Inc
2024/02/2808:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
2024/02/2808:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
2024/02/2808:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
2024/02/2808:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
2024/02/2808:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
2024/02/2808:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
2024/02/2806:05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in MarchNASDAQ:EXELExelixis Inc
2024/02/2408:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXELExelixis Inc
2024/02/2307:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
2024/02/1709:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
2024/02/1323:19Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:EXELExelixis Inc
2024/02/0706:49Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EXELExelixis Inc
2024/02/0706:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EXELExelixis Inc
2024/02/0706:05Business WireExelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
2024/02/0206:05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in FebruaryNASDAQ:EXELExelixis Inc
2024/01/2522:00Business WireExelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024NASDAQ:EXELExelixis Inc
2024/01/2406:05Business WireExelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024NASDAQ:EXELExelixis Inc
2024/01/2307:00Business WireOpdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell CarcinomaNASDAQ:EXELExelixis Inc
2024/01/1906:05Business WireEuropean Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) TabletsNASDAQ:EXELExelixis Inc
2024/01/1710:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
2024/01/1710:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
 검색 관련기사 보기:NASDAQ:EXEL

최근 히스토리

NASDAQ
FTOCW
FTAC Olympus Acquisition
COIN
MAGICETH
MAGIC
FX
ZARXOF
ZAR vs XOF
AMEX
XSOE
WisdomTree Emerging Mkts...
TSX
HSL
Horizons Active Floating...
COIN
STNNBTC
POLO
LQDRUSDT
Liquid Driver
BIT
F21913
Vontobel Financial Produ...
ASX
IRX
InhaleRx
BIT
UB7HRB
Unicredit Bank
ASX
YALN
NASDAQ
DWMC
AdvisorShares Dorsey Wri...
BIT
UC08KH
Unicredit Bank
NYSE
BLD
TopBuild
NYSE
ABN-BL
NEO
EPGC
Emerge EMPWR Sustainable...
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유